DR-10625

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameDR-10625

Drug Alias NameDR-10625

ClassificationBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionFibroblast growth factor 21 agonistsGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists

TargetsFibroblast growth factor 21Glucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor

Therapy Area/IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesZhejiang Doer Biologics Corp

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Doer Biologics Corp

Inactive CompaniesN/A

Active IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A